| Literature DB >> 35344244 |
Luigi Basso1, Renato Pietroletti2, Alessandro Micarelli3,4, Agreta Bicaj1, Umberto Costi1, Daniele Crocetti1, Giuseppe D'Ermo1, Gaetano Gallo5.
Abstract
AIM: We present the outcomes and the recurrences of 848 patients with pilonidal disease (PD) treated by biopsy punch excision (BPE) and we weigh our results against progressively obtained operative experience. BPE is a modified 'merged' version of both the Bascom 'pit picking' procedure and the Gips procedure. It employs biopsy punches of different calibre, depending on whether treatment is in the natal cleft (calibre as small as possible) or lateral (larger calibre punches or even small incision). Sometimes this procedure is referred to as the Bascom-Gips procedure.Entities:
Keywords: Bascom; Gips; biopsy; cyst; minimally invasive surgery; pilonidal; punch; sinus
Mesh:
Year: 2022 PMID: 35344244 PMCID: PMC9541250 DOI: 10.1111/codi.16126
Source DB: PubMed Journal: Colorectal Dis ISSN: 1462-8910 Impact factor: 3.917
FIGURE 1Coring out is performed by the biopsy punch, under guidance of the surgical probe
FIGURE 2Coring out by the punch biopsy is completed
FIGURE 3The removed specimen includes pilonidal cyst and fistula
FIGURE 4Cumulative recurrences in followed up patients at 12, 24 and 60 months after surgery
FIGURE 5Number of recurrences (on y axis) plotted against the cumulative cases (on x axis) grouped per 50
Recurrences in followed up patients
| Recurrences | Total |
| |
|---|---|---|---|
| 12 months | 59 (8.1%) | 725 | 17.65 |
| 24 months | 89 (13%) | 682 | |
| 60 months | 98 (16.4%) | 595 | |
| Subsets |
| ||
| 2011–2012 | 29 (12.8%) | 225 | 8.53 |
| 2013–2014 | 19 (6.6%) | 285 | |
| 2015–2016 | 11 (5.1%) | 215 | |
|
| |||
| 2011–2012 | 36 (15.9%) | 226 | 2.38 |
| 2013–2014 | 31 (12.8%) | 242 | |
| 2015–2016 | 22 (10.2%) | 214 | |
|
| |||
| 2011–2012 | 38 (19.5%) | 194 | 2.23 |
| 2013–2014 | 36 (16.7%) | 215 | |
| 2015–2016 | 24 (12.9%) | 186 |
Number of recurrences in patients undergoing 12‐, 24‐ and 60‐month follow‐up.
| Item No | Recommendation | Page | |
|---|---|---|---|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 1 |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 3 | ||
| Introduction | |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| Methods | |||
| Study design | 4 | Present key elements of study design early in the paper | 5 |
| Setting | 5 | Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow‐up and data collection | 5–6 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow‐up | 5–6 |
| (b) For matched studies, give matching criteria and number of exposed and unexposed | |||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders and effect modifiers. Give diagnostic criteria, if applicable | 5–7 |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 7 |
| Study size | 10 | Explain how the study size was arrived at | 6 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 7 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 7 |
| (b) Describe any methods used to examine subgroups and interactions | |||
| (c) Explain how missing data were addressed | |||
| (d) If applicable, explain how loss to follow‐up was addressed | |||
| (e) Describe any sensitivity analyses | |||
| Results | |||
| Participants | 13* | (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow‐up, and analysed | 7–8 |
| (b) Give reasons for non‐participation at each stage | |||
| (c) Consider use of a flow diagram | |||
| Descriptive data | 14* | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | 7–8 |
| (b) Indicate number of participants with missing data for each variable of interest | |||
| (c) Summarize follow‐up time (e.g., average and total amount) | |||
| Outcome data | 15 | Report numbers of outcome events or summary measures over time | 7–8 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder‐adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 7–8 |
| (b) Report category boundaries when continuous variables were categorized | |||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |||
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | 7–8 |
| Discussion | |||
| Key results | 18 | Summarize key results with reference to study objectives | 9 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 10 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 9–10 |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results | 9–10 |
| Other information | |||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 2 |